Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript

So in practice the scheme that you’re talking about of titration is really only a construct of clinical trials. In practice that doctors naturally titrate by starting on a low dose waiting, observing and then going to the next dose and the next dose. Now with regards to the construct in clinical trials, we’re very happy with the tolerability profile of pemvidutide as we’ve currently developed. We know that the allowance of dose reduction which happens all the time in clinical practice, but specifically allowed and all of the other obesity trials will greatly enhance the tolerability profile of the compound. We’re seeing single digit adverse event discontinuation rates in our MASH – in our D trials and our diabetes trials. We saw no adverse events discontinuations at all.

And — 1.8 milligram dose there was no nausea reported. So that aside from the obesity population, this drug is very well-tolerated. That being the case there is the optionality to pursue longer dose titration in a Phase 3 program. It’s something that we’ve considered it something on the table as we go forward into discussions with the FDA.

Jon Wolleban: Very helpful color, Scott. Looking forward to seeing those details when you announce them.

Scott Harris: Thanks Jonathan.

Operator: Thank you. At this time, I am showing no further questions. I would now like to turn the conference back over to Vipin Garg for closing remarks.

Vipin Garg: Thank you. Thank you everyone for participating today. We appreciate this opportunity to share our results and outlook with you and thank you for your continued support and have a wonderful day.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.